What if cardiovascular disease prevention had a once-a-year solution? That’s the next-gen future that the executives at Corsera Health imagine. The company, which is pairing therapeutics with a ...

BOSTON--(BUSINESS WIRE)--Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced it has raised $80 million in a Series A ...

Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced it has raised $80 million in a Series A financing. Forbion and ...

The cardiovascular biotech was also named as one of BioSpace’s top startups to watch on Wednesday. Cardiovascular disease biotech Corsera Health, which was named Wednesday as one of BioSpace’s NextGen ...

Corsera Health Inc. has filed a clinical trial notification (CTN) seeking to initiate a phase I trial of COR-1004 in New Zealand. COR-1004 is a novel investigational subcutaneously administered siRNA ...

Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to initiate a Phase 1 clinical ...

– Late-breaking presentation at ESC Congress 2025 confirms that early, persistent lowering of LDL-C and blood pressure leads to improved cardiovascular health outcomes – – Raised over $50 million to ...

Industry giants Clive Meanwell, M.D., and John Maraganore, Ph.D., have unveiled Corsera Health, a new biotech aiming to disrupt the cardiovascular landscape with a once-annual preventive heart disease ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.